Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefdinir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 0.79 |
| ▸ | APAF1 | O14727 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.79 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.79 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.79 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.78 |
| ▸ | MMP2 | P08253 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefdinir SCHEMBL3299566 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL36995 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL6820723 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL5919457 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL3297328 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL16072816 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL1559599 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL36996 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL4114437 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL4114446 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137496-A1 | COMPOSITIONS AND METHODS OF USING CPG OLIGONUCLEOTIDES | SIX THERAPEUTICS INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-3534900-A1 | METHODS AND COMPOSITIONS FOR ATTENUATING ANTIBIOTIC RESISTANCE | Synthetic Biologics, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3474885-A1 | MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS | Synthetic Biologics, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2018175414-A1 | BETA-LACTAMASE FORMULATIONS | SYNTHETIC BIOLOGICS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| EP-3344325-A1 | LOCAL ADMINISTRATION OF DRUGS FOR THE TREATMENT OF ASTHMA | Mercator Medsystems, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2018005606-A1 | MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS | SYNTHETIC BIOLOGICS, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| EP-3236993-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICS | Synthetic Biologics Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3166959-A1 | TARGETING PEPTIDES THAT BIND S. MUTANS, CONSTRUCTS COMPRISING SUCH PEPTIDES AND USES THEREOF | C3 Jian, Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2017040605-A1 | LOCAL ADMINISTRATION OF DRUGS FOR THE TREATMENT OF ASTHMA | MERCATOR MEDSYSTEMS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2016105498-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICS | SYNTHETIC BIOLOGICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016007551-A1 | TARGETING PEPTIDES THAT BIND S. MUTANS, CONSTRUCTS COMPRISING SUCH PEPTIDES AND USES THEREOF | C3 JIAN, INC. (US) | 2016-01-14 | — | — | WO | disclosed |
| WO-2011084882-A2 | METHODS AND COMPOSITIONS FOR ENHANCED IMMUNOLOGICAL THERAPY AND TARGETING OF GRAM-POSITIVE BACTERIA | CONTRAFECT CORPORATION (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2010009735-A2 | COMBINATORIAL ANALYSIS AND REPAIR | DAKO DENMARK A/S (DK) | 2010-01-28 | — | — | WO | disclosed |